{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 28,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/10",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.15,
        "x": 0.82,
        "y": 0.3
      },
      "kind": "callout",
      "text": "BENEFITS OF TARGETING CD40: Both immunity arms: More powerful response; Upstream of T-cell activation: Enable T cell response; Modulates tumor microenvironment: Cold -> hot tumor",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04475789-460d-4422-8294-02afa36e92c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.32,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Biological pathway diagram showing CD40 agonist activation of innate and adaptive immune cells leading to tumoricidal activity.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37baaa9e-88ab-42d6-aa40-ab79504cf598",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.06,
        "y": 0.5
      },
      "kind": "list",
      "text": "Therapeutic index; Toxicity; Only effective in subset of patients; Adaptive but not innate immunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "345870c0-c2dc-46eb-bc57-0dfdfe440d81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.06,
        "y": 0.0019
      },
      "kind": "paragraph",
      "text": "CHECKPOINT INHIBITORS: Great Promise but Also Challenges",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f5c2673-51b5-41a5-a248-d79d5252bf1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Targeting CD40: A Key Pathway in Stimulating Immune Response in Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6e95aee-37a3-49a6-9747-76e14b57290b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "cf2ade2d-f00f-40fa-8a0f-9569a750612a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Sotigalimab as a potential first-in-class CD40 agonist antibody and describes the APXiMAB platform.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 15,
      "from": 10,
      "beatId": "eabcce46-c7fe-4e05-b519-ae0aa88c80cb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The deck provides details on Sotigalimab's clinical development program and potential applications.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "3eb55c6a-aa43-4de6-9bf7-e2573f2f45ff",
      "evidence": "The deck describes Sotigalimab's mechanism of action and potential advantages.",
      "position": 1,
      "objective": "Explain how Sotigalimab works and its potential benefits",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}